Ro15-2041 is a selective platelet phosphodiesterase inhibitor with antithrombotic properties; it inhibits platelet aggregation induced by common platelet agonists, potentiates prostacyclin-induced platelet inhibition and elevation of intraplatelet cyclic AMP levels, inhibits collagen-induced release of serotonin and beta-thromboglobulin, reduces thrombin-induced increases in cytosolic free Ca²⁺ and accelerates its normalization in human platelets.